Axogen Inc. released a corporate presentation outlining its focus on peripheral nerve repair across multiple U.S. markets, including extremities, breast reconstruction, oral maxillofacial and head and neck procedures, and prostate surgery. The presentation highlights the company’s nerve repair approach and product portfolio, including Avance nerve graft, Axoguard products, and Avive+, and discusses market development priorities such as surgeon education, clinical evidence generation, coverage expansion, and commercial infrastructure growth. It also notes expectations for improved U.S. outpatient facility reimbursement for allograft nerve repair procedures tied to a new CMS outpatient code grouping in 2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axogen Inc. published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.